Letrozol Sandoz

Letrozole, the active ingredient in Letrozol Sandoz, is an aromatase inhibitor presented as an oral tablet for oral use. It is indicated for hormone receptor‑positive breast cancer in postmenopausal women, where it lowers estrogen production to help control tumor growth.

GNH USA supplies Letrozol Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Letrozol Sandoz is an aromatase inhibitor used in the management of estrogen‑dependent breast cancer. It works within the hormone‑driven pathway to reduce circulating estrogen.

- Hormone receptor‑positive breast cancer (postmenopausal): Decreases estrogen levels to inhibit tumor proliferation. - Adjuvant therapy for early‑stage breast cancer: Helps prevent disease recurrence after surgery. - Metastatic breast cancer (postmenopausal): Provides disease control when cancer has spread beyond the breast.

Letrozol Sandoz may cause a range of adverse reactions, most of which are mild to moderate in severity.

Common Side Effects: - Hot flashes: Sudden feeling of warmth, often with sweating. - Joint and muscle pain: Arthralgia or myalgia affecting daily activities. - Fatigue: Persistent tiredness not relieved by rest. - Nausea: Mild to moderate upset stomach. - Headache: Tension‑type or throbbing pain. - Dizziness: Light‑headed sensation, especially on standing.

Serious or Rare Side Effects: - Severe liver injury: Jaundice, dark urine, or elevated liver enzymes. - Bone fractures: Increased risk of osteoporosis‑related breaks. - Pulmonary embolism: Sudden shortness of breath, chest pain, or coughing up blood. - Allergic reactions: Rash, swelling, or anaphylaxis. - Elevated cholesterol: Significant rise in LDL levels. - QT interval prolongation: Potential cardiac rhythm disturbances.

Before initiating Letrozol Sandoz, clinicians should evaluate patient history and monitor specific parameters. - Bone health assessment: Perform baseline bone mineral density testing and consider calcium/vitamin D supplementation. - Liver function monitoring: Check hepatic enzymes periodically during therapy. - Cardiovascular risk: Assess lipid profile and manage hypercholesterolemia as needed. - Pregnancy and lactation: Contraindicated; ensure effective contraception in women of child‑bearing potential. - Store at ambient temperature: Keep below 25 °C, in the original container, protected from moisture and direct sunlight.

Letrozol Sandoz can interact with other medicines that affect estrogen pathways or CYP enzymes.

Major Interactions (Avoid): - Estrogen‑containing hormone therapy: Counteracts the drug’s estrogen‑lowering effect. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): May markedly reduce letrozole plasma concentrations.

Moderate Interactions (Monitor Closely): - CYP2A6 or CYP3A4 inhibitors (e.g., fluconazole, ketoconazole): May increase exposure and risk of toxicity. - Warfarin: Potential for altered anticoagulant effect; monitor INR. - Cholesterol‑lowering agents (e.g., statins): May require lipid monitoring due to possible additive effects on cholesterol levels.